Innate Pharma SA
Melanie Douville is an experienced finance professional currently serving as the Director of Accounting Consolidation & Treasury at Innate Pharma since May 2020, where responsibilities include overseeing a team of four and managing financial aspects of reports such as 20F and URD, in addition to being the process owner for Consolidation and Tax credit. Prior to this role, Melanie held several positions at LE TEMPS DES CERISES JEANS from June 2014 to May 2020, including Head of Accounting Consolidation & Treasury and Accounting Manager, focusing on team management, treasury oversight, and fiscal responsibilities. Melanie's earlier career includes roles at Ball Packaging Europe, GSE, and KPMG, specializing in accounting management and auditing. Melanie holds a degree from NEOMA Business School.
This person is not in any teams
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.